Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Postow
    Postow
  4. Segal
    Segal
  5. Voss
    Voss
  6. Bajorin
    Bajorin
  7. Budhu
    Budhu
  8. Joseph
    Joseph
  9. Khalil
    Khalil
  10. Ostrovnaya
    Ostrovnaya

Groups

  1. Department of Medicine (41)
  2. Solid Tumor Oncology Division (32)
  3. GSK Faculty (24)
  4. Population Sciences Research Program (14)
  5. Sloan Kettering Institute Postdocs (14)
  6. Center for Hematologic Malignancies (11)
  7. Melanoma and Immunotherapeutics Service (11)
  8. Epidemiology and Biostatistics (10)
  9. Hematologic Malignancies, Division of (10)
  10. Sloan Kettering Institute Faculty (10)
Search Within
  1. "2016"
Formats
  1. Journal Article (50)
  2. Meeting Abstract (25)
Groups
  1. Department of Medicine (41)
  2. Solid Tumor Oncology Division (32)
  3. GSK Faculty (24)
  4. Population Sciences Research Program (14)
  5. Sloan Kettering Institute Postdocs (14)
  6. Center for Hematologic Malignancies (11)

More Groups

People
  1. Jedd Wolchok (8)
  2. Taha Merghoub (7)
  3. Andrew Vickers (4)
  4. Jianda Yuan (3)
  5. Kenneth Offit (3)
  6. Margaret Callahan (3)

More People

Years
  1. 2016 (75)
Publications
  1. Journal for ImmunoTherapy of Cancer (31)
  2. Breast Cancer Research (8)
  3. BMC Cancer (5)
  4. Genome Medicine (3)
  5. Genome Biology (2)
  6. Health and Quality of Life Outcomes (2)

More Publications

Results (75)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genome-scale neoantigen screening using ATLAS™ prioritizes candidates for immunotherapy in a non-small cell lung cancer patient
    Meeting Abstract

    Ghamsari, L.; Flano, E.; Jacques, J.; Liu, B.; Havel, J.; Makarov, V.; Merghoub, T.; Wolchok, J. D.; Hellmann, M. D.; Chan, T. A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Intratumoral delivery of modified vaccinia virus Ankara expressing human flt3L as cancer immunotherapy
    Meeting Abstract

    Dai, P.; Wang, W.; Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J. D.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Opposing effects of CTLA-4 and PD-1 blockade on follicular helperlike T cells with immunosuppressive functions
    Meeting Abstract

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M.; Senbabaoglu, Y.; Gasmi, B.; Zhong, H.; Li, Y.; Liu, C.; Hirschhorhn-Cymerman, D.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies
    Meeting Abstract

    Lipson, E.; Gopal, A.; Neelapu, S. S.; Armand, P.; Spurgeon, S.; Leonard, J. P.; Hodi, F. S.; Sanborn, R. E.; Melero, I.; Gajewski, T. F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Patel, M.; Falchook, G.; Pant, S.; Ott, P. A.; Whiteside, M.; Patnaik, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to control tumors systemically
    Meeting Abstract

    Khalil, D. N.; Campesato, L. F.; Li, Y.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Johnson, M. L.; Adjei, A. A.; Opyrchal, M.; Ramalingam, S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; de Leon, L.; Hasapidis, J.; Diede, S. J.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with checkpoint blockade and tumor radiation therapy promotes anticancer activity in mouse melanoma
    Meeting Abstract

    Budhu, S.; De Henau, O.; Zappasodi, R.; Schlunegger, K.; Freimark, B.; Hutchins, J.; Barker, C. A.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer
    Meeting Abstract

    Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save